Home › Compare › TOKTY vs ABBV
TOKTY yields 56.98% · ABBV yields 3.06%● Live data
📍 TOKTY pulled ahead of the other in Year 1
Combined, TOKTY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TOKTY + ABBV for your $10,000?
Tokai Tokyo Financial Holdings, Inc. operates as a securities company in Japan. The company provides foreign equities, foreign bonds, structured bonds, and derivatives; investment trust services; and investment banking services, such as IPOs, public stock offerings, secondary sales, and mergers and acquisitions (M&A). Its activities also include financial instruments business; research on economic conditions and corporate performance; creation and management of funds, and self-financed investments; consulting on handling of testamentary trusts and inheritance property; asset management; fund investment; education and training; provision of transfer agency, merchandising, printing, real-estate rental management, and insurance agency services; and back-office operations. In addition, the company offers M&A, and cross-border advisory services; and investment management, advisory, and agency services. The company was formerly known as Tokai Tokyo Securities Co., Ltd. and changed its name to Tokai Tokyo Financial Holdings, Inc. in April 2009. Tokai Tokyo Financial Holdings, Inc. was incorporated in 1929 and is headquartered in Tokyo, Japan.
Full TOKTY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.